Royce & Associates LP grew its holdings in MaxCyte, Inc. (NASDAQ:MXCT - Free Report) by 146.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 799,873 shares of the company's stock after purchasing an additional 475,949 shares during the period. Royce & Associates LP owned approximately 0.76% of MaxCyte worth $3,327,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Franklin Resources Inc. purchased a new stake in shares of MaxCyte in the third quarter valued at $260,000. Barclays PLC lifted its holdings in shares of MaxCyte by 329.3% in the third quarter. Barclays PLC now owns 165,765 shares of the company's stock valued at $645,000 after purchasing an additional 127,156 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of MaxCyte by 2.0% in the third quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company's stock valued at $9,628,000 after purchasing an additional 47,960 shares in the last quarter. Mudita Advisors LLP lifted its holdings in shares of MaxCyte by 5.6% in the third quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company's stock valued at $12,267,000 after purchasing an additional 167,101 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of MaxCyte by 5.1% in the third quarter. State Street Corp now owns 2,269,135 shares of the company's stock valued at $8,827,000 after purchasing an additional 111,066 shares in the last quarter. Hedge funds and other institutional investors own 68.81% of the company's stock.
MaxCyte Stock Performance
Shares of NASDAQ MXCT traded up $0.02 during mid-day trading on Friday, reaching $3.09. The company had a trading volume of 1,083,993 shares, compared to its average volume of 509,903. MaxCyte, Inc. has a twelve month low of $2.76 and a twelve month high of $5.26. The stock has a market capitalization of $327.63 million, a PE ratio of -9.09 and a beta of 1.35. The stock's 50 day moving average is $4.04 and its 200-day moving average is $3.93.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on MXCT. BTIG Research set a $6.00 price target on shares of MaxCyte and gave the stock a "buy" rating in a research note on Wednesday, March 12th. Stifel Nicolaus dropped their price target on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th.
Check Out Our Latest Stock Analysis on MXCT
MaxCyte Profile
(
Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Recommended Stories
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
